Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).
Ashraf Badros(University of Maryland, Baltimore), Merrill J. Egorin(Beth Israel Deaconess Medical Center), Carolynn Harris(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), S. Philip(University of Maryland, Baltimore), Olga Goloubeva(University of Maryland, Baltimore), James Zweibel, Rubén Niesvizky(Cornell University), James R. Wright(Duke University), Stefan C. Grant, A. M. Burger(Centre National de la Recherche Scientifique)
Cited by 25
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795